IDO rout: Piv­otal tri­als with Bris­tol-My­ers, Mer­ck and As­traZeneca dumped in wake of In­cyte's PhI­II im­plo­sion

The IDO R&D pipeline is in dan­ger of be­ing ex­ter­mi­nat­ed.

In the wake of a piv­otal fail­ure of In­cyte’s $IN­CY lead IDO drug epaca­do­stat, Bris­tol-My­ers Squibb $BMY be­came the third play­er forced to re­trench in that im­muno-on­col­o­gy field, drop­ping three late-stage stud­ies of a ri­val drug it bagged in a $1.25 bil­lion buy­out. But that was just the start of a rout.

In­cyte re­port­ed this morn­ing that its wide-rang­ing col­lab­o­ra­tions with Big Phar­ma play­ers are com­ing un­done. In their Q1 an­nounce­ment, echo­ing the fail­ure of ECHO-301, the com­pa­ny not­ed:

En­roll­ment will be dis­con­tin­ued in the four ad­di­tion­al piv­otal tri­als of epaca­do­stat in com­bi­na­tion with pem­brolizum­ab (Mer­ck’s Keytru­da), and in the two piv­otal tri­als of epaca­do­stat in com­bi­na­tion with nivolum­ab (Bris­tol-My­ers’ Op­di­vo); each of these stud­ies will be amend­ed to en­able pa­tients and their physi­cians to con­sid­er al­ter­na­tive ther­a­peu­tic op­tions. The piv­otal tri­al in com­bi­na­tion with dur­val­um­ab (As­traZeneca’s Imfinzi) in Stage 3 lung can­cer will not be ini­ti­at­ed.

A spokesper­son for As­traZeneca al­so tells me that there is “an­oth­er Phase II (com­bi­na­tion study) in sol­id tu­mors and we’re go­ing to stop en­roll­ment there too.” That will be all for the ECHO-203 study — epaca­do­stat plus dur­val­um­ab again. “In­cyte did present some da­ta from ECHO-203 at AACR: 15 pa­tients with pan­cre­at­ic can­cer were en­rolled across mul­ti­ple dose lev­els, no clin­i­cal ac­tiv­i­ty was ob­served.”

In ad­di­tion, In­cyte said that it is “sig­nif­i­cant­ly down­siz­ing the epaca­do­stat de­vel­op­ment pro­gram,” sig­nal­ing a painful re­treat for a one-time star drug that com­mand­ed pro­jec­tions of block­buster peak sales.

Ac­cord­ing to clin­i­cal­tri­als.gov, in­ves­ti­ga­tors for the big biotech to­day ter­mi­nat­ed a Phase III study of BMS-986205 in com­bi­na­tion with Bris­tol-My­ers’ Op­di­vo for front­line head and neck can­cer. An­oth­er Phase III study for front­line Stage IV or re­cur­rent non-small cell lung can­cer us­ing BMS-986205 and Op­di­vo with or with­out chemo ver­sus chemo alone was with­drawn. And there’s a third study for melanoma that’s now ac­tive but not re­cruit­ing af­ter en­list­ing 72 pa­tients.

A spokesper­son for Bris­tol-My­ers told us Mon­day night:

Based on emerg­ing da­ta on the IDO path­way, we closed reg­is­tra­tional stud­ies of our IDO in­hibitor, BMS-986205, in melanoma, SC­CHN and NSCLC. We re­main com­mit­ted to con­tin­ued re­search of BMS-986205-based com­bi­na­tions in an in­formed and sci­en­tif­i­cal­ly ro­bust man­ner. We will con­tin­ue to eval­u­ate BMS-986205-based com­bi­na­tions in our Phase 1/2 study, CA017-003.

Sep­a­rate­ly, we are work­ing quick­ly with In­cyte to as­sess our pro­gram un­der the col­lab­o­ra­tion.

NewLink $NLNK was the first to over­haul its ap­proach on IDO fol­low­ing the In­cyte dis­as­ter.  The biotech scrapped a melanoma study that would have eval­u­at­ed in­dox­i­mod in com­bi­na­tion with check­point in­hibitors Keytru­da or Op­di­vo in 600 pa­tients. In a press re­lease, NewLink ex­plained the de­ci­sion was made “in the con­text of the fail­ure of a com­peti­tor’s tri­al of its en­zy­mat­ic IDO in­hibitor in a sim­i­lar clin­i­cal set­ting.

Bris­tol-My­ers’ de­ci­sion — first re­port­ed by Xcon­o­my — un­der­scores a grow­ing be­lief that In­cyte’s fail­ure was as much a fail­ure of the class as an in­di­vid­ual ther­a­py, po­ten­tial­ly tor­pe­do­ing a wide swath of clin­i­cal tri­als now in the pipeline.

In­cyte frankly con­ced­ed that its piv­otal fail­ure raised doubts about its en­tire ef­fort, which in­cludes a host of com­bi­na­tion stud­ies with check­point lead­ers like Mer­ck and As­traZeneca. In this case, Bris­tol-My­ers is cut­ting back on a drug that it ac­quired in a block­buster deal to ac­quire Flexus 3 years ago. In­ves­ti­ga­tors have re­peat­ed­ly tout­ed the drug as a po­ten­tial lynch­pin in im­muno-on­col­o­gy, fo­cus­ing on an en­zyme that sup­press­es the im­mune cells Op­di­vo and a whole new class of PD-1/L1 check­points are de­signed to un­leash in an at­tack on can­cer cells.

Iron­i­cal­ly, In­cyte has been pur­su­ing lit­i­ga­tion against one of its for­mer sci­en­tists, claim­ing he de­fect­ed to Flexus with IDO trade se­crets in hand, well be­fore the buy­out. Bris­tol-My­ers, though, has stead­fast­ly as­sert­ed — with some sup­port from an­a­lysts — that it had the bet­ter IDO that could leapfrog epaca­do­stat. The leap­ing in IDO, though, has stopped. At least for now.

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)

What kind of PhI­Ib da­ta is worth $4B cash? Take­da’s Andy Plump has some thoughts on that

A few months back, when Takeda caused jaws to drop with its eye-watering $4 billion cash upfront for a mid-stage TYK2 drug from Nimbus, it had already taken a deep dive on the solid Phase IIb data Nimbus had assembled from its dose-ranging study in psoriasis.

Now, it’s rolling that data out, eager to demonstrate what inspired the global biopharma to go long in a neighboring, but new, disease arena for the pipeline. And the most avid students of the numbers will likely be at Bristol Myers Squibb, who will have a multi-year head start on pioneering the TYK2 space with Sotyktu (deucravacitinib) as Takeda makes its lunge for best-in-class status.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA in­di­cates will­ing­ness to ap­prove Bio­gen ALS drug de­spite failed PhI­II study

Ahead of Wednesday’s advisory committee hearing to discuss Biogen’s ALS drug tofersen, the FDA appeared open to approving the drug, newly released briefing documents show.

Citing the need for flexibility in a devastating disease like ALS, regulators signaled a willingness to consider greenlighting tofersen based on its effect on a certain protein associated with ALS despite a failed pivotal trial. The documents come after regulatory flexibility was part of the same rationale the agency expressed when approving an ALS drug last September from Amylyx Pharmaceuticals, indicating the FDA’s openness to approving new treatments for the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

No­vo Nordisk re­mains un­der UK scruti­ny as MHRA con­ducts its own re­view in 'in­cred­i­bly rare' case

The UK’s Medicines and Healthcare products Regulatory Agency is now reviewing Novo Nordisk’s marketing violation that resulted in its loss of UK trade group membership last week. Novo Nordisk was suspended on Thursday from the Association of the British Pharmaceutical Industry (ABPI) for two years after an investigation by its regulatory arm found the pharma broke its conduct rules.

MHRA said on Tuesday that its review of the Prescription Medicines Code of Practice Authority (PMCPA) investigation is standard practice. An MHRA spokesperson emphasized in an email to Endpoints News that the situation with Novo Nordisk is “incredibly rare” while also noting ABPI took “swift and proportionate action.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Vipin Garg, Altimmune CEO

Al­tim­mune’s shares halved af­ter in­ter­im look at PhII weight loss drug da­ta

Altimmune’s attempt to catch up to Novo Nordisk and Eli Lilly’s GLP-1 drugs hit an investor snag Tuesday after the biotech shared interim Phase II weight loss data.

The Maryland biotech’s pemvidutide is a GLP-1/glucagon dual receptor agonist meant to activate GLP-1 receptors to squash appetite and glucagon to ramp up energy use. The 2.4 mg dose showed a placebo-adjusted weight loss of 9.7% at week 24 of 48, which Jefferies analysts said would be comparable to Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Mounjaro).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

FDA warns Proc­ter & Gam­ble over NyQuil la­bel's in­gre­di­ent list­ings

The FDA on Tuesday released a warning letter sent earlier this month to the Mason, OH-based site of Procter & Gamble Manufactura, raising questions about the list of ingredients on the label and in the electronic filing.

The warning says that for P&G’s over-the-counter Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion, there’s a “mismatched” list of active ingredients between the labeling and the electronic listing file. The listing file for the active ingredients did not match the active ingredients in the electronic file.

FTC says patent bat­tle over Parkin­son's drug could have 'sig­nif­i­cant im­pli­ca­tion­s' for pa­tients

The Federal Trade Commission has gotten involved in a patent feud over Supernus’ Parkinson’s drug Apokyn, a case the agency said may have ‘‘significant implications” for patients who rely on the drug.

Sage Chemical won the first generic approval for its Apokyn formulation (also known as apomorphine hydrochloride injection) back in 2022. The non-ergoline dopamine agonist is approved to treat Parkinson’s symptoms during “off episodes,” such as difficulty moving, tremors and intense cramping. However, regulators specified that the approval pertained to the generic drug cartridges only, not the injector pen required for administration.

Harpreet Singh, Immatics CEO

Im­mat­ics an­nounces mul­ti­ple pipeline changes with lat­est fi­nan­cial re­sults

The T-cell biotech Immatics is looking to make some changes to its pipeline.

Immatics released its 2022 financial results on Tuesday and announced that it’s planning to discontinue its program for IMA201, an experimental cell therapy for solid tumors that express the antigens known as MAGE4/8. It plans to shift focus to IMA401, a TCR bispecific which goes after the same target.

The German-based biotech said it will treat the remaining patients enrolled in the program before the discontinuation. No other reasons were given for the discontinuation. Endpoints News reached out to Immatics for more details but did not receive a response by press time.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Mar­ket­ingRx roundup: What could a US Tik­Tok ban mean for phar­ma? Pfiz­er, Lil­ly lead phar­ma March Mad­ness ad­ver­tis­ers

Just as pharma marketers finally make moves into TikTok, the threat of a US ban on the social media channel is now looming. Already banned on federal employee phones by an initial Congressional act, more bills and maybe bans are on the way. With rare bipartisan agreement, lawmakers have introduced legislation that would give the US president the power to ban TikTok (although not mentioned by name) and other foreign-owned technology platforms that represent a security threat to the US.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.